By Delilah Alvarado | May 14, 2026
In a significant vote of confidence for the next generation of precision oncology and immunology, Cambridge-based biotechnology firm Create Medicines announced on Thursday that it has successfully closed a $122 million Series B financing round. The capital infusion is earmarked to accelerate the development of the company’s proprietary RNA-based, in vivo CAR-T cell therapy platform, which seeks to transform the treatment landscape for both malignant cancers and complex autoimmune conditions.
The financing was co-led by a powerhouse consortium of existing investors, including Arch Venture Partners, Newpath Partners, and Hatteras Venture Partners. Participation also extended to Alexandria Venture Investments and several other members of the company’s established investor syndicate, underscoring the strong institutional backing for Create’s bold approach to immune-cell reprogramming.
The Core Innovation: Moving Beyond the Lab
At the heart of Create Medicines’ value proposition is a radical departure from the traditional, labor-intensive manufacturing process that has historically defined CAR-T cell therapies. Conventional CAR-T treatments—such as those approved for blood cancers—require the extraction of a patient’s T cells, complex genetic modification in an external laboratory, and a lengthy infusion cycle. This "ex vivo" process is not only time-consuming and expensive but also often inaccessible to patients who require immediate intervention.
Create Medicines is pioneering an in vivo approach. By utilizing a sophisticated messenger RNA (mRNA) and lipid nanoparticle (LNP) delivery platform, the company can deliver therapeutic genetic instructions directly into the patient’s body. Once administered, these nanoparticles home in on specific immune cells—T cells, NK cells, and myeloid cells—instructing them to reprogram themselves to identify and combat disease. The result, according to the company, is a “one-day manufacturing process” that could democratize access to cell therapy and significantly reduce the logistical hurdles associated with current standards of care.
Chronology: From Myeloid Therapeutics to Create Medicines
The journey to this $122 million milestone has been characterized by strategic pivots and high-profile scientific leadership.
- 2021: The Genesis of Myeloid Therapeutics: The company launched as Myeloid Therapeutics with over $50 million in initial financing. Founded by renowned cell therapy visionaries Ronald Vale, an entrepreneur and co-founder of Cytokinetics, and Siddhartha Mukherjee, the biologist and Pulitzer Prize-winning author, the startup initially focused on harnessing myeloid cells to target tumors.
- 2023-2024: The Strategic Pivot: Recognizing the broader potential of their mRNA-based delivery system, the leadership team expanded the company’s scope beyond myeloid cells to address a wider array of immune-mediated diseases. This transition signaled a move toward a more versatile, platform-centric model.
- 2025: Rebranding: Reflecting this evolution, the firm officially rebranded from Myeloid Therapeutics to Create Medicines, signaling its commitment to a broader portfolio of therapeutic applications.
- May 2026: The successful closure of the $122 million Series B round marks the company’s most significant financial milestone to date, providing the runway necessary to move multiple programs through clinical development.
Supporting Data and Clinical Momentum
Create Medicines enters this new phase of growth with a substantial clinical footprint. To date, the company has dosed more than 50 patients across its various programs—a figure it claims represents the largest clinical dataset in the in vivo cell therapy field.
The most recent clinical milestone occurred just last month, when the company successfully dosed the first patient in a Phase 1/2 clinical trial for its lead candidate, MT-304. This first-in-class, multi-immune in vivo CAR therapy is designed to target the HER2 protein, which is frequently overexpressed in breast cancer and other solid tumors, including gastric cancer. Unlike traditional single-target therapies, MT-304 is engineered to trigger multiple arms of the immune system simultaneously, potentially overcoming the resistance mechanisms that often plague conventional monotherapies.
Beyond oncology, the company is aggressively applying its technology to the autoimmune space. By targeting CD19 and BCMA—proteins that have become the "gold standard" targets in FDA-approved CAR-T medicines for blood cancers—Create Medicines is testing whether its in vivo platform can reset the immune systems of patients suffering from severe, treatment-resistant autoimmune conditions.
Leadership Expansion and Governance
To steer the company through this high-growth period, Create Medicines has appointed biotech veteran Ron Philip as Executive Chairman. Philip brings extensive experience in drug development and commercialization, which is expected to be vital as the company transitions from early-stage clinical research to larger, multi-site trials.
“I’m excited to join Create at this pivotal moment in the company’s evolution,” Philip said in a statement. “Create has established meaningful in vivo clinical proof points and built a differentiated immune programming platform with the potential to redefine how engineered immune therapies are developed and delivered.”
The governance structure has also been bolstered by the addition of Brian Cuneo, a senior partner at Arch Venture Partners, and Tom Thomas, a senior associate of Newpath Partners, to the company’s board of directors. These appointments signal a deepening of ties with the venture capital firms that have been instrumental in the company’s trajectory.
Implications: The Future of Cell Therapy
The success of Create Medicines’ funding round has profound implications for the biotechnology sector at large.
1. The Democratization of CAR-T
If in vivo CAR-T therapy proves to be as effective and scalable as early data suggests, it could lead to the "democratization" of cell therapy. By eliminating the need for expensive, centralized manufacturing facilities, in vivo treatments could be shipped as off-the-shelf therapies, allowing community hospitals to administer complex genetic medicines that currently require specialized, tertiary academic centers.
2. Broadening the Therapeutic Window
While CAR-T has been a triumph in hematological malignancies (blood cancers), its efficacy in solid tumors has been limited. Create Medicines’ strategy of activating multiple immune cell types, rather than relying solely on T cells, may be the key to unlocking solid tumor therapy. By expanding this to autoimmune diseases, the company is effectively positioning its platform as a "universal immune-modulator."
3. Investor Sentiment and Market Outlook
The $122 million round is a clear signal that investors are still hungry for transformative platform technologies, despite a cautious macroeconomic environment. The willingness of existing syndicates to double down on Create Medicines suggests that the "clinical proof-of-concept" phase is yielding results that satisfy even the most rigorous institutional investors.
4. Competitive Landscape
Create Medicines is not alone in this race. Numerous startups and established giants are experimenting with various delivery methods—ranging from viral vectors to advanced lipid nanoparticles—to achieve in vivo cell reprogramming. However, with its large patient dataset and diversified pipeline, Create is positioning itself as a leader in the space. The coming 18 to 24 months, as data from the MT-304 trial matures, will likely determine whether the company can maintain its current competitive advantage.
Conclusion
The $122 million Series B financing represents more than just capital; it is a validation of the shift toward "in-body" genetic medicine. By moving away from the cumbersome ex vivo manufacturing paradigm, Create Medicines is attempting to bridge the gap between complex science and patient-centered healthcare.
With a seasoned leadership team, a robust clinical data set, and a platform that addresses some of the most significant challenges in modern medicine, the company is set to play a pivotal role in the future of immune-mediated therapeutics. As the clinical trials for MT-304 and its autoimmune programs progress, the scientific community will be watching closely to see if the promise of "one-day" reprogramming can truly change the trajectory for patients worldwide.
About the Author
